Sveriges Riksbank
Bid date, 2021-03-18 | |
Bid Date | 2021-03-18 |
Bid times | 14.00-14.30 (CET/CEST) on the Bid date |
Offered Amount | USD 10 billion |
Maximum Permitted Volume of Bids | USD 4 billion from an individual institution |
Settlement Date | 2021-03-22 |
Minimum Permitted Bid Volume | 100 USD million per bid |
Maximum Allocation | 40 per cent of the Offered amount |
Allocation time | Not later than 15.00 (CET/CEST) on the Bid date |
Maturity Date | 2021-06-14 |
Maximum Number of Bids | 10 per individual institution |
Lowest Interest Supplement | 0.25 percentage points |
Confirmation of bids to e-mail | eol@riksbank.se |
Stockholm, 2021-03-16
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom